S180: RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN TRIAL

MLA

C. Hasselbalch Riley, et al. “S180: Rg6234, a Novel Gprc5d T-Cell Engaging Bispecific Antibody, Induces Rapid Responses in Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a First-In-Human Trial.” HemaSphere, vol. 6, June 2022, pp. 81–82. EBSCOhost, https://doi.org/10.1097/01.HS9.0000843612.41180.42.

APA

C. Hasselbalch Riley, M. Hutchings, S.-S. Yoon, Y. Koh, S. Manier, T. Facon, S. J. Harrison, J. Er, F. Volzone, A. Pinto, C. Montes, E. M. Ocio, A. Alfonso-Pierola, P. Rodriguez Otero, F. Offner, A. Guidetti, P. Corradini, C. Titouan, C. Hulin, … C. Carlo-Stella. (2022). S180: Rg6234, a Novel Gprc5d T-Cell Engaging Bispecific Antibody, Induces Rapid Responses in Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a First-In-Human Trial. HemaSphere, 6, 81–82. https://doi.org/10.1097/01.HS9.0000843612.41180.42

Chicago

C. Hasselbalch Riley, M. Hutchings, S.-S. Yoon, Y. Koh, S. Manier, T. Facon, S. J. Harrison, et al. 2022. “S180: Rg6234, a Novel Gprc5d T-Cell Engaging Bispecific Antibody, Induces Rapid Responses in Patients with Relapsed/Refractory Multiple Myeloma: Preliminary Results from a First-In-Human Trial.” HemaSphere 6 (June): 81–82. doi:10.1097/01.HS9.0000843612.41180.42.